Damora Therapeutics Inc
Follow $DMRA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $DMRA by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredsnapshot unavailable for DMRA. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is DMRA moving today?
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
DMRA overview
Related filings and maps
Congress activity in DMRA
No receipt-qualified filings found.
DMRA contract awards, year to date.
Public federal awards linked to this ticker.
DMRA lobbying filings, year to date.
Registered lobbying filings matched to Damora Therapeutics Inc.